This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (87)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Diagnosis  • Neoplasms  • Alert me on articles by topic

Data From the 1973 Through 1994 Surveillance, Epidemiology, and End Results Program Registry

Leslie K. Dennis, PhD

Arch Dermatol. 1999;135:275-280.

Background  The incidence of melanoma has been increasing faster than that of any other cancer in the United States. It is unclear whether the increase is related to increased surveillance or other changes in the disease.

Objective  To examine changes in melanoma rates by several measures of severity of disease and to review the ways in which increased surveillance may cause lead-time bias through early detection or length bias through detection of clinically insignificant lesions as a basis for interpreting these changing rates.

Design  Population-based incidence rates for 1973 through 1994.

Setting  United States Surveillance, Epidemiology, and End Results Program tumor registries.

Patients  A total of 47,638 cases of melanoma among white patients aged 20 years and older.

Main Outcome Measures  Relative incidence rates for melanoma by stage, and tumor thickness adjusted for age and sex.

Results  Localized-stage melanoma increased, but no significant change for distant-stage melanomas was seen. Among those diagnosed from 1988 through 1994, there were 22%, 26%, and 31% increases for tumor thickness less than 1.0 mm, between 1.0 and 3.0 mm, and 3.0 mm or greater, respectively. The 2-year mortality rates also increased over time.

Conclusions  While these data show large increases in early disease (localized stage, thin tumors), they also suggest some increase in advanced disease (thick tumors, 2-year mortality). This indicates that the increasing incidence rates of melanoma are not solely caused by increased early detection and diagnosis of clinically insignificant melanomas, but may also represent a true increase in cancer rates.

From the Department of Epidemiology and Biostatistics and the Ireland Cancer Center, Division of General Medical Sciences (Oncology), School of Medicine, Case Western Reserve University, Cleveland, Ohio.

RELATED ARTICLE

Archives of Dermatology Reader's Choice: Continuing Medical Education
Arch Dermatol. 1999;135(3):358-359.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Skin Diseases in Family Medicine: Prevalence and Health Care Use
Verhoeven et al.
Ann Fam Med 2008;6:349-354.
ABSTRACT | FULL TEXT  

Synthesis and Biologic Evaluation of 64Cu-Labeled Rhenium-Cyclized {alpha}-MSH Peptide Analog Using a Cross-Bridged Cyclam Chelator
Wei et al.
JNM 2007;48:64-72.
ABSTRACT | FULL TEXT  

Galectin-3 Expression Is Associated with Tumor Progression and Pattern of Sun Exposure in Melanoma.
Prieto et al.
Clin. Cancer Res. 2006;12:6709-6715.
ABSTRACT | FULL TEXT  

Educational Outcomes Regarding Skin Cancer in Organ Transplant Recipients: Randomized Intervention of Intensive vs Standard Education.
Clowers-Webb et al.
Arch Dermatol 2006;142:712-718.
ABSTRACT | FULL TEXT  

Eugenol Causes Melanoma Growth Suppression through Inhibition of E2F1 Transcriptional Activity
Ghosh et al.
J. Biol. Chem. 2005;280:5812-5819.
ABSTRACT | FULL TEXT  

Prognostic Factors of Thin Cutaneous Melanoma: An Analysis of the Central Malignant Melanoma Registry of the German Dermatological Society
Leiter et al.
JCO 2004;22:3660-3667.
ABSTRACT | FULL TEXT  

Etiologic Pathogenesis of Melanoma: A Unifying Hypothesis for the Missing Attributable Risk
Meyskens et al.
Clin. Cancer Res. 2004;10:2581-2583.
FULL TEXT  

A Gallium-Labeled DOTA-{alpha}-Melanocyte- Stimulating Hormone Analog for PET Imaging of Melanoma Metastases
Froidevaux et al.
JNM 2004;45:116-123.
ABSTRACT | FULL TEXT  

An Endogenous Retrovirus Derived from Human Melanoma Cells
Muster et al.
Cancer Res. 2003;63:8735-8741.
ABSTRACT | FULL TEXT  

The Melanoma Epidemic: Res Ipsa Loquitur
Beddingfield
The Oncologist 2003;8:459-465.
ABSTRACT | FULL TEXT  

DOTA {alpha}-Melanocyte-Stimulating Hormone Analogues for Imaging Metastatic Melanoma Lesions
FROIDEVAUX et al.
Ann. N. Y. Acad. Sci. 2003;994:378-383.
ABSTRACT | FULL TEXT  

A Novel DOTA-{alpha}-Melanocyte-Stimulating Hormone Analog for Metastatic Melanoma Diagnosis
Froidevaux et al.
JNM 2002;43:1699-1706.
ABSTRACT | FULL TEXT  

Instrumental Measurements of Skin Color and Skin Ultraviolet Light Sensitivity and Risk of Cutaneous Malignant Melanoma: A Case-Control Study in an Italian Population
Brenner et al.
Am J Epidemiol 2002;156:353-362.
ABSTRACT | FULL TEXT  

Nodular Type and Older Age as the Most Significant Associations of Thick Melanoma in Victoria, Australia
Chamberlain et al.
Arch Dermatol 2002;138:609-614.
ABSTRACT | FULL TEXT  

Thin Melanomas and Regression, Thick Melanomas and Older Men: Prognostic Implications and Perspectives on Secondary Prevention
Demierre
Arch Dermatol 2002;138:678-682.
FULL TEXT  

DNA Repair, Dysplastic Nevi, and Sunlight Sensitivity in the Development of Cutaneous Malignant Melanoma
Landi et al.
JNCI J Natl Cancer Inst 2002;94:94-101.
ABSTRACT | FULL TEXT  

Recent Trends in Cutaneous Melanoma Incidence Among Whites in the United States
Jemal et al.
JNCI J Natl Cancer Inst 2001;93:678-683.
ABSTRACT | FULL TEXT  

Cancer Surveillance Series: Changing Patterns of Cutaneous Malignant Melanoma Mortality Rates Among Whites in the United States
Jemal et al.
JNCI J Natl Cancer Inst 2000;92:811-818.
ABSTRACT | FULL TEXT  

Melanoma and the Dermatologist in the Third Millennium
MacKie
Arch Dermatol 2000;136:71-73.
FULL TEXT